Lingotto Investment Management LLP
Position in RXRX — Recursion Pharmaceuticals, Inc.
CIK 1732768
London, X0
Position in RXRX
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$18,056,935
-$2,111,088 QoQ
Shares Held
5,881,738
+19.3% QoQ
Ownership
1.11%
of shares outstanding
% of Portfolio
0.43%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
12 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RXRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Lingotto Investment Management LLP holds $56,863,410 across 2 Biotechnology names. RXRX ranks #2 (31.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRNA |
Moderna, Inc.
|
763,907 | $38,806,475 | |
| 2 | RXRX |
Recursion Pharmaceuticals, Inc.
This page
|
5,881,738 | $18,056,935 |
All Filings in RXRX
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $18,056,935 | 5,881,738 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $20,168,023 | 4,931,057 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $17,934,375 | 3,675,077 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $18,595,889 | 3,675,077 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $19,441,157 | 3,675,077 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $24,843,520 | 3,675,077 | Shares | Defined | 2025-02-04 | |
| 2024-09-30 | $24,218,757 | 3,675,077 | Shares | Defined | 2024-11-13 | |
| 2024-06-30 | $27,563,077 | 3,675,077 | Shares | Defined | 2024-08-12 | |
| 2024-03-31 | $21,685,517 | 2,175,077 | Shares | Defined | 2024-05-15 | |
| 2023-12-31 | $18,488,259 | 1,875,077 | Shares | Defined | 2024-02-13 | |
| 2023-09-30 | $5,929,339 | 775,077 | Shares | Defined | 2023-11-13 | |
| 2023-06-30 | $5,789,825 | 775,077 | Shares | Defined | 2023-08-11 | |
| No filing history on record for this holder in this stock. | ||||||